73.79
price up icon1.30%   0.95
after-market 시간 외 거래: 73.75 -0.04 -0.05%
loading
전일 마감가:
$72.84
열려 있는:
$73.7
하루 거래량:
3.43M
Relative Volume:
0.68
시가총액:
$228.77B
수익:
$54.07B
순이익/손실:
$7.04B
주가수익비율:
32.72
EPS:
2.255
순현금흐름:
$7.28B
1주 성능:
-1.52%
1개월 성능:
-2.46%
6개월 성능:
-4.93%
1년 성능:
+8.92%
1일 변동 폭
Value
$73.43
$74.19
1주일 범위
Value
$71.82
$75.12
52주 변동 폭
Value
$62.75
$87.67

아스트라제네카 ADR Stock (AZN) Company Profile

Name
명칭
Astrazeneca PLC
Name
전화
44 20 3749 5000
Name
주소
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Name
직원
61,100
Name
트위터
@AstraZeneca
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
AZN's Discussions on Twitter

AZN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Major icon
AZN
Astrazeneca PLC
73.79 228.77B 54.07B 7.04B 7.28B 2.255

아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-13 업그레이드 UBS Neutral → Buy
2025-02-12 개시 Morgan Stanley Overweight
2024-11-20 업그레이드 UBS Sell → Neutral
2024-11-06 업그레이드 Deutsche Bank Sell → Hold
2024-09-13 다운그레이드 Deutsche Bank Hold → Sell
2024-05-30 개시 Goldman Buy
2024-04-16 업그레이드 Deutsche Bank Sell → Hold
2024-02-08 다운그레이드 Deutsche Bank Hold → Sell
2024-01-23 개시 Morgan Stanley Overweight
2024-01-16 재개 UBS Sell
2024-01-03 다운그레이드 Jefferies Buy → Hold
2023-12-18 개시 HSBC Securities Buy
2023-09-25 업그레이드 Jefferies Hold → Buy
2023-07-14 개시 HSBC Securities Buy
2023-07-12 업그레이드 UBS Neutral → Buy
2023-07-05 다운그레이드 Deutsche Bank Buy → Hold
2023-04-11 업그레이드 Morgan Stanley Equal-Weight → Overweight
2023-01-05 개시 BMO Capital Markets Outperform
2022-09-15 다운그레이드 Credit Suisse Outperform → Neutral
2022-09-07 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2022-08-29 업그레이드 Argus Hold → Buy
2022-06-14 다운그레이드 UBS Buy → Neutral
2022-02-11 업그레이드 DZ Bank Sell → Hold
2021-12-07 다운그레이드 Jefferies Buy → Hold
2021-08-12 재개 JP Morgan Overweight
2021-04-12 다운그레이드 Argus Buy → Hold
2021-03-16 업그레이드 Jefferies Hold → Buy
2021-02-25 업그레이드 UBS Neutral → Buy
2021-01-15 개시 Deutsche Bank Buy
2020-12-07 업그레이드 Morgan Stanley Equal-Weight → Overweight
2020-11-30 업그레이드 UBS Sell → Neutral
2020-11-11 업그레이드 HSBC Securities Reduce → Hold
2020-09-29 개시 Berenberg Buy
2019-11-22 개시 SVB Leerink Outperform
2019-10-25 업그레이드 Liberum Hold → Buy
2019-04-02 다운그레이드 UBS Neutral → Sell
2019-02-05 개시 Exane BNP Paribas Outperform
2019-01-25 업그레이드 Shore Capital Hold → Buy
2018-12-11 재개 Jefferies Hold
2018-10-09 개시 Guggenheim Buy
2018-08-16 다운그레이드 Jefferies Buy → Hold
2018-03-19 업그레이드 Jefferies Hold → Buy
2018-02-06 재확인 Leerink Partners Mkt Perform
2018-02-05 재확인 Bernstein Outperform
2018-01-18 재확인 Leerink Partners Mkt Perform
2017-12-29 업그레이드 JP Morgan Neutral → Overweight
2017-10-16 업그레이드 Credit Suisse Neutral → Outperform
2017-09-25 업그레이드 Exane BNP Paribas Neutral → Outperform
2017-09-22 업그레이드 Bernstein Mkt Perform → Outperform
모두보기

아스트라제네카 ADR 주식(AZN)의 최신 뉴스

pulisher
11:43 AM

J&J Passes AstraZeneca in Lung Cancer Drug Race — For Now - MSN

11:43 AM
pulisher
Mar 29, 2025

SFJ Pharmaceuticals & SERB Pharmaceuticals Present Positive Final Results from Pivotal Ph 3 REVERSE-IT Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Surgery or Experiencing Major Bleeding - GlobeNewswire Inc.

Mar 29, 2025
pulisher
Mar 29, 2025

AstraZeneca Pharma India to discontinue manufacturing, marketing of angina drug from April 1 - Medical Dialogues

Mar 29, 2025
pulisher
Mar 28, 2025

AstraZeneca's Imfinzi gains additional indication for bladder cancer - Seeking Alpha

Mar 28, 2025
pulisher
Mar 28, 2025

AstraZeneca (AZN) Gains FDA Approval for New Imfinzi Indication - GuruFocus.com

Mar 28, 2025
pulisher
Mar 28, 2025

Is AstraZeneca (AZN) the Best ADR Stock to Buy According to Hedge Funds? - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

AstraZeneca PLC ADR outperforms competitors on strong trading day - MarketWatch

Mar 28, 2025
pulisher
Mar 28, 2025

AstraZeneca Sues Consultancy For £32M Over HQ Defects - Law360

Mar 28, 2025
pulisher
Mar 28, 2025

Goldman Sachs maintains AstraZeneca stock with $98 target By Investing.com - Investing.com UK

Mar 28, 2025
pulisher
Mar 28, 2025

Goldman Sachs lifts AstraZeneca stock target, sees growth By Investing.com - Investing.com UK

Mar 28, 2025
pulisher
Mar 27, 2025

AstraZeneca Fights Generic Diabetes Drug Launch - Law360

Mar 27, 2025
pulisher
Mar 27, 2025

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Berenberg Keeps AstraZeneca at Buy on Pipeline Potential - Marketscreener.com

Mar 27, 2025
pulisher
Mar 26, 2025

Del. Justices Back Axing Suit Over $3B AstraZeneca Viela Sale - Law360

Mar 26, 2025
pulisher
Mar 26, 2025

J&J passes AstraZeneca in lung cancer drug race — for now - Crain's New York Business

Mar 26, 2025
pulisher
Mar 26, 2025

J&J’s Rybrevant-Lazcluze Combo Tops AstraZeneca’s Drug in EGFR Lung CancerJohnson & Johnson (NYSE:JNJ) - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

J&J Passes AstraZeneca in Blockbuster Cancer Race — For Now - Bloomberg

Mar 26, 2025
pulisher
Mar 26, 2025

AstraZeneca's Win in Shareholder Suit Over Viela Sale Affirmed - Bloomberg Law

Mar 26, 2025
pulisher
Mar 26, 2025

China on track to outpace Europe in pharmaceutical innovation, says AstraZeneca CEO By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

China on track to outpace Europe in pharmaceutical innovation, says AstraZeneca CEO - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Europe Rapidly Falling Behind China in Pharma, AstraZeneca CEO Warns - Bloomberg

Mar 26, 2025
pulisher
Mar 26, 2025

Whittier Trust Co. Boosts Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat

Mar 26, 2025
pulisher
Mar 25, 2025

Astrazeneca invests in China: $8B in deals, $2.5B in R&D center - BioWorld Online

Mar 25, 2025
pulisher
Mar 25, 2025

Astrazeneca Says Tagrisso Shows Improved Overall Survival Trend In Laura Phase 3 Trial - Marketscreener.com

Mar 25, 2025
pulisher
Mar 25, 2025

AstraZeneca Seeks to Move Past China Probe With R&D Hub - Bloomberg

Mar 25, 2025
pulisher
Mar 25, 2025

AstraZeneca seeks to move past China probe with Beijing R&D hub - The Edge Malaysia

Mar 25, 2025
pulisher
Mar 24, 2025

AstraZeneca PLC ADR underperforms Monday when compared to competitors - MarketWatch

Mar 24, 2025
pulisher
Mar 24, 2025

Assemblin to upgrade AstraZeneca’s Gärtuna plant in Sweden - Yahoo Finance

Mar 24, 2025
pulisher
Mar 24, 2025

AstraZeneca and GKS shares have legs, but the weight loss titans will dominate, says investment bank - Proactive Investors UK

Mar 24, 2025
pulisher
Mar 24, 2025

Prediction: 12 months from now, AstraZeneca’s share price could be… - Yahoo Finance UK

Mar 24, 2025
pulisher
Mar 24, 2025

AstraZeneca to invest $2.5bn in R&D centre in China - Pharmaceutical Technology

Mar 24, 2025
pulisher
Mar 24, 2025

Assemblin Caverion Group Unit to Upgrade AstraZeneca's Swedish Plant -March 24, 2025 at 03:37 am EDT - Marketscreener.com

Mar 24, 2025
pulisher
Mar 23, 2025

Top global stories of the week: AstraZeneca, BYD, SoftBank among notable names - Seeking Alpha

Mar 23, 2025
pulisher
Mar 23, 2025

AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica

Mar 23, 2025
pulisher
Mar 21, 2025

AstraZeneca Expands Emphasis On China, Already A Key Market - News & Insights

Mar 21, 2025
pulisher
Mar 21, 2025

AstraZeneca PLC ADR falls Friday, underperforms market - MarketWatch

Mar 21, 2025
pulisher
Mar 21, 2025

Sector Update: Health Care Stocks Retreat Late Afternoon -March 21, 2025 at 03:50 pm EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

AstraZeneca to invest $2.5bn in China after snub for UK plant - The Times

Mar 21, 2025
pulisher
Mar 21, 2025

AstraZeneca To Invest $2.5B In China Research Hub - Law360

Mar 21, 2025
pulisher
Mar 21, 2025

Sector Update: Health Care Stocks Fall in Afternoon Trading -March 21, 2025 at 01:50 pm EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

Sector Update: Health Care -March 21, 2025 at 01:39 pm EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

Going in vivo: AstraZeneca acquires EsoBiotec in potential $1bn deal - BioXconomy

Mar 21, 2025
pulisher
Mar 21, 2025

AstraZeneca deepens China investment; Editas loses CFO to Dyne - BioPharma Dive

Mar 21, 2025
pulisher
Mar 21, 2025

HBM Holdings To Issue To Astrazeneca Holdings Subscription Shares -March 21, 2025 at 11:28 am EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

Kangtai Biological Products To Establish JV With AstraZeneca -March 21, 2025 at 10:40 am EDT - Marketscreener.com

Mar 21, 2025
pulisher
Mar 21, 2025

AstraZeneca to invest £2bn in Beijing amid China investigation - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Micron, Johnson & Johnson, AstraZeneca: Top Stocks - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Astrazeneca enters multispecific antibody collaborations with CEPI, Harbour Biomed - BioWorld Online

Mar 21, 2025
pulisher
Mar 21, 2025

AstraZeneca to make a $2.5B investment in China (AZN:NASDAQ) - Seeking Alpha

Mar 21, 2025
pulisher
Mar 21, 2025

AstraZeneca invests US$2.5 bil in Beijing hub amid probe - The Edge Malaysia

Mar 21, 2025

아스트라제네카 ADR (AZN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
자본화:     |  볼륨(24시간):